Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results Nov 7, 2023 04:05PM
Zymeworks Announces Participation in Upcoming Investor Conferences Nov 1, 2023 08:30AM
Zymeworks To Host Third Quarter 2023 Results Conference Call Oct 17, 2023 08:30AM
Zymeworks (ZYME) Appoints Nancy Davidson to its Board Oct 16, 2023 04:32PM
Zymeworks Announces New Director Nominee Oct 16, 2023 04:30PM
View Older Stories

Aug 10, 2023 04:05PM Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Aug 10, 2023 04:05PM Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Aug 1, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Jul 19, 2023 08:30AM Zymeworks To Host Second Quarter 2023 Results Conference Call
Jul 3, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conference
Jun 29, 2023 04:05PM Zymeworks (ZYME) Appoints Carlos E. Campoy to its Board
Jun 29, 2023 04:05PM Zymeworks Appoints New Director
Jun 26, 2023 08:43AM Zymeworks (ZYME) Set to Join Russell 3000, Russell 2000, and Russell Microcap Indexes
Jun 26, 2023 08:30AM Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
Jun 5, 2023 05:53AM Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) Present Positive Pivotal Phase 2b Trial Data
Jun 2, 2023 06:41PM Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Jun 1, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
May 18, 2023 08:32AM Zymeworks (ZYME) Announces Departure of Neil Klompas, President and Chief Operating Officer
May 18, 2023 08:30AM Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
May 8, 2023 04:05PM Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 8, 2023 04:05PM Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 1, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
May 1, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Apr 18, 2023 04:07PM Zymeworks (ZYME) Presents New Data from Multiple Preclinical and Clinical Development Programs
Apr 18, 2023 04:05PM Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
Apr 18, 2023 04:05PM Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
Apr 17, 2023 08:30AM Zymeworks To Host First Quarter 2023 Results Conference Call
Apr 10, 2023 08:31AM Zymeworks (ZYME) Announces Appointment of Derek J. Miller to its Board of Directors
Apr 10, 2023 08:30AM Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
Apr 3, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Mar 14, 2023 04:30PM Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
Mar 7, 2023 04:05PM Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 28, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Feb 21, 2023 08:30AM Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
Jan 25, 2023 08:30AM Zymeworks Announces Participation in Upcoming Investor Conferences
Jan 19, 2023 07:46AM Jazz Pharmaceuticals (JAZZ), Zymeworks (ZYME) Announce 84% OS at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Jan 19, 2023 07:45AM Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Jan 4, 2023 04:15PM Zymeworks (ZYME) Provides Update on Key Strategic Priorities and Outlook for 2023
Jan 4, 2023 04:15PM Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
Dec 21, 2022 07:30AM Jazz (JAZZ) and Zymeworks (ZYME) Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Dec 21, 2022 07:30AM Zymeworks Announces Participation in Upcoming Investor Conference
Dec 21, 2022 07:30AM Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Dec 19, 2022 07:04AM Zymeworks (ZYME) Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Dec 19, 2022 07:00AM Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Dec 14, 2022 04:15PM Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Dec 9, 2022 08:03AM Zymeworks (ZYME) Announces New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
Dec 9, 2022 08:00AM New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
Dec 5, 2022 08:30AM Zymeworks to Transfer Stock Listing to Nasdaq
Nov 29, 2022 08:31AM Zymeworks (ZYME) Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
Nov 29, 2022 08:30AM Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
Nov 22, 2022 08:30AM Zymeworks Announces Participation in Upcoming Investor Conference
Nov 21, 2022 09:00AM Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Nov 8, 2022 04:22PM Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Oct 20, 2022 08:30AM Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
Oct 19, 2022 06:07AM Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
View Older Stories